Novel & Combination therapies in MDS Results in SF3B1, Cytidine Deaminase Inhibitors, Decitabine

Marlise R. Luskin, MD, MSCE, Johns Hopkins University School of Medicine, discusses Novel & Combination therapies in MDS Results in SF3B1, Cytidine Deaminase Inhibitors, Decitabine at Imedex Great Debates 2018.